Notícias e Atividades da Hepion Pharmaceuticals

Hepion Pharmaceuticals é uma empresa listada sob o símbolo HEPA (US).

Fusão, aquisição e financiamento envolvendo Hepion Pharmaceuticals.

• Hepion Pharmaceuticals and Pharma Two B have announced they will merge  (publicado em 8 de agosto de 2024)..

Veja o organograma con seus 4 executivos principais

Biografias mais buscadas da Hepion Pharmaceuticals

• Kaouthar Lbiati, Interim Chief Executive Officer
• Timothy Block, Director
• Michael Purcell, Director

Recentes movimentos de executivos em Hepion Pharmaceuticals

• Kaouthar Lbiati antes Director, foi promovido a Interim Chief Executive Officer  (Notícia publicada em 17 de junho de 2025).
• John Brancaccio, Interim Chief Executive Officer, Interim Chief Financial Officer and Chairman of the Board, se aposentou  (Notícia publicada em 17 de junho de 2025).

Criar um alerta
para seguir os movimentos de executivos da Hepion Pharmaceuticals.

Hepion Pharmaceuticals possui 1.837 concorrentes concorrentes Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) e Sanofi (França).

Popular M&A news in Farmacêutica

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (publicado em 16 de junho de 2025).
• Juvenescence acaba de anunciar uma arrecadação de fundos de 76 milhões de dólares. (publicado em 22 de maio de 2025).
• Kincell Bio acaba de anunciar uma arrecadação de fundos de 22 milhões de dólares. (publicado em 22 de maio de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations da Abeona Therapeutics
• Keiichi Ando - Independent Non-Executive Director da Shionogi

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Hepion Pharmaceuticals

• Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces Reverse Stock Split – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces $9.0 Million Public Offering – Hepion Pharmaceuticals
• Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. – Hepion Pharmaceuticals
• Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B – Hepion Pharmaceuticals
• Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger – Hepion Pharmaceuticals
• Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger – Hepion Pharmaceuticals
• Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement – Hepion Pharmaceuticals
• View more press releases Close

Redes sociais sobre Hepion Pharmaceuticals

• Hepion Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Hepion Pharmaceuticals na LinkedIn, Twitter e YouTube